Brief: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
30/09/2025 12:03
Sept 30 (Reuters) - Opus Genetics Inc IRD.O: OPUS GENETICS REPORTS POSITIVE PEDIATRIC DATA FROM OPGX-LCA5 PHASE 1/2 TRIAL IN LEBER CONGENITAL AMAUROSIS TYPE 5 (LCA5) OPUS GENETICS INC - OPGX-LCA5 WELL-TOLERATED IN ALL PARTICIPANTS Source text: ID:nGNX5JgZPK Further company coverage: IRD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data